135 related articles for article (PubMed ID: 9486679)
21. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs.
Tompa DR; Immanuel A; Srikanth S; Kadhirvel S
Int J Biol Macromol; 2021 Mar; 172():524-541. PubMed ID: 33454328
[TBL] [Abstract][Full Text] [Related]
22. The immunorecognition, subcellular compartmentalization, and physicochemical properties of nucleic acid nanoparticles can be controlled by composition modification.
Johnson MB; Halman JR; Miller DK; Cooper JS; Khisamutdinov EF; Marriott I; Afonin KA
Nucleic Acids Res; 2020 Nov; 48(20):11785-11798. PubMed ID: 33091133
[TBL] [Abstract][Full Text] [Related]
23. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
24. The road to new antiviral therapies.
Jerome KR
Clin Appl Immunol Rev; 2005; 5(1):65-76. PubMed ID: 32362789
[TBL] [Abstract][Full Text] [Related]
25. Topical application of temperature-sensitive caerin 1.1 and 1.9 gel inhibits TC-1 tumor growth in mice.
Ma B; Yuan J; Chen S; Huang K; Wang Q; Ma J; Lin R; Zhang L; Zhou Y; Wang T; Walton SF; Pan X; Chen G; Wang Y; Ni G; Liu X
Am J Transl Res; 2020; 12(1):191-202. PubMed ID: 32051748
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.
Liou AT; Liao CC; Chou SF; Chang YS; Chang CS; Shih C
J Biomed Sci; 2019 Nov; 26(1):93. PubMed ID: 31711481
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis.
Barton S; Wakefield V; O'Mahony C; Edwards S
BMJ Open; 2019 Oct; 9(10):e027765. PubMed ID: 31676644
[TBL] [Abstract][Full Text] [Related]
28. Co-Delivery of Imiquimod and Plasmid DNA via an Amphiphilic pH-Responsive Star Polymer that Forms Unimolecular Micelles in Water.
Lin W; Yao N; Li H; Hanson S; Han W; Wang C; Zhang L
Polymers (Basel); 2016 Nov; 8(11):. PubMed ID: 30974677
[TBL] [Abstract][Full Text] [Related]
29. Position statement for the diagnosis and management of anogenital warts.
O'Mahony C; Gomberg M; Skerlev M; Alraddadi A; de Las Heras-Alonso ME; Majewski S; Nicolaidou E; Serdaroğlu S; Kutlubay Z; Tawara M; Stary A; Al Hammadi A; Cusini M
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1006-1019. PubMed ID: 30968980
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
Murray ML; Meadows J; Doré CJ; Copas AJ; Haddow LJ; Lacey C; Jit M; Soldan K; Bennett K; Tetlow M; Nathan M; Gilson R
BMC Med Res Methodol; 2018 Nov; 18(1):125. PubMed ID: 30400777
[TBL] [Abstract][Full Text] [Related]
31. The Diagnostic and Therapeutic Challenge of Anal Intraepithelial Neoplasia.
Rider P; Hunter J; Grimm L
Curr Gastroenterol Rep; 2018 Jul; 20(8):38. PubMed ID: 29974261
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.
van der Kolk T; Assil S; Rijneveld R; Klaassen ES; Feiss G; Florencia E; Prens EP; Burggraaf J; Moerland M; Rissmann R; van Doorn MBA
Clin Transl Sci; 2018 Nov; 11(6):607-615. PubMed ID: 29768709
[TBL] [Abstract][Full Text] [Related]
33. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.
Vijay K
Int Immunopharmacol; 2018 Jun; 59():391-412. PubMed ID: 29730580
[TBL] [Abstract][Full Text] [Related]
34. Genital warts treatment: Beyond imiquimod.
Yuan J; Ni G; Wang T; Mounsey K; Cavezza S; Pan X; Liu X
Hum Vaccin Immunother; 2018 Jul; 14(7):1815-1819. PubMed ID: 29505317
[TBL] [Abstract][Full Text] [Related]
35. Podophyllotoxin: a novel potential natural anticancer agent.
Ardalani H; Avan A; Ghayour-Mobarhan M
Avicenna J Phytomed; 2017; 7(4):285-294. PubMed ID: 28884079
[TBL] [Abstract][Full Text] [Related]
36. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota.
Shannon B; Yi TJ; Perusini S; Gajer P; Ma B; Humphrys MS; Thomas-Pavanel J; Chieza L; Janakiram P; Saunders M; Tharao W; Huibner S; Shahabi K; Ravel J; Rebbapragada A; Kaul R
Mucosal Immunol; 2017 Sep; 10(5):1310-1319. PubMed ID: 28120845
[TBL] [Abstract][Full Text] [Related]
37. Adjuvants for peptide-based cancer vaccines.
Khong H; Overwijk WW
J Immunother Cancer; 2016; 4():56. PubMed ID: 27660710
[TBL] [Abstract][Full Text] [Related]
38. Moving forward with human papillomavirus immunotherapies.
Çuburu N; Schiller JT
Hum Vaccin Immunother; 2016 Nov; 12(11):2875-2880. PubMed ID: 27388123
[TBL] [Abstract][Full Text] [Related]
39. Approved Antiviral Drugs over the Past 50 Years.
De Clercq E; Li G
Clin Microbiol Rev; 2016 Jul; 29(3):695-747. PubMed ID: 27281742
[TBL] [Abstract][Full Text] [Related]
40. TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.
Abt MC; Buffie CG; Sušac B; Becattini S; Carter RA; Leiner I; Keith JW; Artis D; Osborne LC; Pamer EG
Sci Transl Med; 2016 Feb; 8(327):327ra25. PubMed ID: 26912904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
